Novartis AG ADR (NVS) News
Filter NVS News Items
NVS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVS News Highlights
- For NVS, its 30 day story count is now at 18.
- Over the past 28 days, the trend for NVS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about NVS are DRUG, III and MS.
Latest NVS News From Around the Web
Below are the latest news stories about NOVARTIS AG that investors may wish to consider to help them evaluate NVS as an investment opportunity.
Why Is Cytokinetics (CYTK) Stock Up 70% Today?With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest. |
Novartis (NVS) Outperforms Broader Market: What You Need to KnowNovartis (NVS) closed at $99.71 in the latest trading session, marking a +1.18% move from the prior day. |
The Zacks Analyst Blog Highlights Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de NemoursProcter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours are part of the Zacks top Analyst Blog. |
Novartis (NVS) Stock Moves -1.17%: What You Should KnowNovartis (NVS) closed the most recent trading day at $97.14, moving -1.17% from the previous trading session. |
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review TagThe FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024. |
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to OtsukaPer the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe. |
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now. |
Amgen finds a new top scientist in Novartis veteran BradnerJay Bradner, a well-known physician-scientist who left Novartis last year amid an organizational shakeup, will now serve a Amgen’s chief scientific officer and head of R&D. |
Novartis (NVS) Stock Sinks As Market Gains: Here's WhyIn the most recent trading session, Novartis (NVS) closed at $98.87, indicating a -0.84% shift from the previous trading day. |
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1; the safety profile of iptacopan was consistent with previously reported data1-3 C3 glomerulopathy (C3G) is an ultra-rare complement-mediated kidney disease, with approximately 50% of patients progressing to kidney failure within 10 years of diagnosis4-7; currently no treatments address the underlying ca |